FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for OZURDEX (dexamethasone intravitreal implant) submitted by Allergan, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema Following Retinal Vein Occlusion
• Noninfectious Posterior Uveitis

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

SUPPL AP for OZURDEX (DEXAMETHASONE)